Roche is not ready to throw in the towel with its Huntington’s disease candidate, tominersen, despite a Phase III failure, and is to start a new trial in the hope it could work in a subgroup of patients.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?